KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) EBT Margin (2016 - 2025)

Historic EBT Margin for Inovio Pharmaceuticals (INO) over the last 17 years, with Q1 2025 value amounting to 37100.3%.

  • Inovio Pharmaceuticals' EBT Margin changed N/A to 37100.3% in Q1 2025 from the same period last year, while for Sep 2025 it was 47654.43%, marking a year-over-year increase of 80433000.0%. This contributed to the annual value of 49509.43% for FY2024, which is 332695600.0% down from last year.
  • Inovio Pharmaceuticals' EBT Margin amounted to 37100.3% in Q1 2025.
  • In the past 5 years, Inovio Pharmaceuticals' EBT Margin ranged from a high of 412.75% in Q3 2022 and a low of 43687.24% during Q4 2022
  • Moreover, its 5-year median value for EBT Margin was 20627.17% (2021), whereas its average is 22946.68%.
  • Data for Inovio Pharmaceuticals' EBT Margin shows a peak YoY increase of 202144200bps (in 2022) and a maximum YoY decrease of -309419600bps (in 2022) over the last 5 years.
  • Inovio Pharmaceuticals' EBT Margin (Quarter) stood at 12745.28% in 2021, then plummeted by -243bps to 43687.24% in 2022, then skyrocketed by 44bps to 24357.91% in 2023, then surged by 32bps to 16682.03% in 2024, then crashed by -122bps to 37100.3% in 2025.
  • Its last three reported values are 37100.3% in Q1 2025, 16682.03% for Q4 2024, and 31648.39% during Q2 2024.